Sex-specific Serum Biomarker Associations with Antidepressant Treatment Outcomes in Depressive Disorders
- Author:
Jae-Min KIM
1
;
Hee-Ju KANG
;
Ju-Wan KIM
;
Min JHON
;
Min-Gon KIM
;
Ju-Yeon LEE
;
Sung-Wan KIM
;
Il-Seon SHIN
Author Information
- Publication Type:Original Article
- From:Clinical Psychopharmacology and Neuroscience 2026;24(1):106-117
- CountryRepublic of Korea
- Language:English
-
Abstract:
Objective:This study examined whether baseline levels of 14 serum biomarkers predicted antidepressant remission differently by sex at 12 weeks and 12 months.
Methods:In a prospective cohort, 1,086 outpatients with depressive disorders received stepwise antidepressant treatment following a naturalistic protocol. Baseline serum samples were analyzed for biomarkers from six systems: immune (high-sensitivity C-reactive protein, tumor necrosis factor-alpha, interleukin-1 beta, interleukin-6, interleukin-4, interleukin-10), metabolic (leptin, ghrelin, total cholesterol), neurotrophic (brain-derived neurotrophic factor), neurotransmitter (serotonin), endocrine (cortisol), and nutritional (folate, homocysteine). Remission, defined as a Hamilton Depression Rating Scale scores ≤ 7, was assessed at 12 weeks and 12 months. Logistic regression models with biomarker-by-sex interaction and stratified analyses were used, adjusting for clinical covariates.
Results:Higher baseline serotonin predicted 12-week remission in males but not in females. At 12 months, lower leptin and higher folate predicted remission only in males, while lower cortisol predicted remission only in females. These showed significant biomarker-sex interactions. No sex-specific interactions were found for immune markers.
Conclusion:Baseline serum biomarkers across biological systems showed sex-specific associations with treatment outcomes. Neurotransmitter, metabolic, endocrine, and nutritional markers may offer predictive value for sex-tailored, biomarker-informed treatment strategies in depression.
